Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Total Equity
Editas Medicine Inc
Total Equity Peer Comparison
Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Total Equity
$294.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$10.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$17.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$5B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-14%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$17.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
32%
|
CAGR 10-Years
29%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$27B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
See Also
What is Editas Medicine Inc's Total Equity?
Total Equity
294.4m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Total Equity amounts to 294.4m USD.
What is Editas Medicine Inc's Total Equity growth rate?
Total Equity CAGR 5Y
6%
Over the last year, the Total Equity growth was -7%. The average annual Total Equity growth rates for Editas Medicine Inc have been -23% over the past three years , 6% over the past five years .